In short
A groundbreaking clinical trial is underway to investigate the potential of Cpft Trifluoroacetate in improving live birth rates for women under 37 years old undergoing Intracytoplasmic Sperm Injection (ICSI). This study aims to evaluate the effectiveness of supplementing culture media with Cpft during the pre-ICSI incubation of oocytes and preimplantation embryo development. The trial, named FERTICSI, offers hope for couples struggling with infertility and seeking assisted reproductive technologies.
At a glance
- Study Name
- FERTICSI: Improvement of Live Babies Rates After ICSI, Using cpFT
- Main Objective
- Improve live birth rates after ICSI using Cpft Trifluoroacetate supplementation
- Participant Age
- Women: 18-36 years, Men: 18-58 years
- Treatment
- Cpft Trifluoroacetate added to culture medium for oocytes and embryos
- Primary Endpoint
- Live baby birth rate after first embryo transfer
- Follow-up Period
- Up to one year after birth
- Key Assessments
- Embryo quality, pregnancy rates, baby health and development
What is CPFT Trifluoroacetate?
CPFT Trifluoroacetate is a new medication being studied to improve the success rates of a specific type of assisted reproductive technology called Intracytoplasmic Sperm Injection (ICSI). ICSI is a procedure where a single sperm is directly injected into an egg to help with fertilization.
How CPFT Trifluoroacetate Works
CPFT Trifluoroacetate is a special type of molecule called a hexapeptide. It mimics a part of a sperm protein called Fertilin β, which is important for the sperm and egg to interact during fertilization. When added to the culture medium (the liquid where eggs and embryos are kept during IVF), CPFT Trifluoroacetate has shown promising results in improving various aspects of assisted reproduction.
Potential Benefits of CPFT Trifluoroacetate
Research has shown that CPFT Trifluoroacetate may offer several benefits in assisted reproduction:
- Increases the maturation of human eggs in the laboratory
- Improves the genetic health (ploidy) of human eggs
- Enhances the development of embryos before implantation in both mice and humans
These improvements could potentially lead to higher success rates in fertility treatments.
Current Clinical Trial: FERTICSI Study
A clinical trial called FERTICSI is currently underway to study the effects of CPFT Trifluoroacetate on improving live birth rates after ICSI. This study is being conducted in multiple centers and involves women under 37 years of age who are undergoing fertility treatment.
Who is Eligible for the FERTICSI Study?
The study includes couples who meet the following criteria:
- Require Medically Assisted Reproduction
- Are eligible for ICSI
- Women aged 18 to 36 years
- Men aged 18 to 58 years
- Affiliated with a Social Security system
Some conditions that would exclude participation include early menopause, certain medical conditions, or the need for egg or sperm donation.
Study Objectives and Endpoints
The main goal of the FERTICSI study is to see if adding CPFT Trifluoroacetate to the culture medium can improve the rate of live births after ICSI. The study will also look at several other important factors, including:
- The quality and development of embryos
- Pregnancy rates and miscarriage rates
- The health of babies during pregnancy and after birth
- The development of children up to one year old
These outcomes will help researchers understand the full impact of CPFT Trifluoroacetate on fertility treatment and child health.
How CPFT Trifluoroacetate is Administered
It's important to note that CPFT Trifluoroacetate is not directly given to patients. Instead, it is added to the culture medium where eggs and embryos are kept during the ICSI procedure. The maximum duration of exposure is 6 days, which covers the time from egg retrieval to embryo transfer or freezing.
Future Implications and Considerations
If the FERTICSI study shows positive results, CPFT Trifluoroacetate could become an important addition to fertility treatments, potentially increasing the success rates of ICSI procedures. However, it's crucial to remember that the study is still ongoing, and more research will be needed to fully understand the long-term effects and benefits of this treatment.
As with any medical treatment, especially those involving assisted reproduction, it's essential to discuss all options, potential benefits, and risks with your healthcare provider. They can provide personalized advice based on your specific situation and the most up-to-date research findings.